Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Syndrome héréditaire de prédisposition au cancer du sein et de l’ovaire : diagnostic et implications thérapeutiques

Autor: N Douay-Hauser, Claude Nos, Pierre Laurent-Puig, Guillaume Achen, Meriem Koual, Huyen-Thu Nguyen-Xuan, Céline Crespel, Hélène Blons, Anne-Sophie Bats, Marie-Aude Le Frère-Belda, Rosa Montero, J. Medioni, Géraldine Perkins, Nicolas Delanoy, Diane Molière, Vincent Balaya

Publikováno v: Annales de Pathologie
Annales de Pathologie, Elsevier Masson, 2020, 40, pp.70-77. ⟨10.1016/j.annpat.2020.01.004⟩

Resume Les patientes porteuses d’une mutation du gene BReast Cancer 1 ou 2 (BRCA) ont une predisposition hereditaire aux cancers du sein et de l’ovaire. Ces mutations genetiques deleteres sont celles les plus couramment impliquees dans les cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b232530e33ffca0d0f9f166d233102
https://doi.org/10.1016/j.annpat.2020.01.004

544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study

Autor: N. Delanoy, E. Ashton, S. Mebarki, M. Gisselbrecht, B. Nicaise, H. Azais, M. Koual, A-S. Bats Mongardon, L. Fournier, M-A. Le Frère-Belda, J. Medioni, E. Paillaud, S. Oudard

Publikováno v: Annals of Oncology. 33:S796

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cccf5d8da023568d03c34b2962fb6bc1
https://doi.org/10.1016/j.annonc.2022.07.672

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203)

Autor: Michele Maio, Yubing Yao, Howard Su-Hau Yeh, Margarita Majem, Slawomir Mandziuk, Michael Schenker, Gwenaelle Gravis, Sulabha Ranganathan, J. Medioni, Mark Cornfeld, Tibor Csőszi

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.2571-2571. ⟨10.1200/JCO.2021.39.15_suppl.2571⟩

2571 Background: Checkpoint inhibitors (CPIs) are an effective treatment (tx) for many tumor types. Retifanlimab, an investigational humanized anti–PD-1 monoclonal antibody, has shown safety, pharmacology, and clinical activity consistent with the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8bbcc73f5abcd957ec8c3b5a592d2c0
https://hal-amu.archives-ouvertes.fr/hal-03623326